The central structural fact
Kairos Pharma, LTD. (NYSE American: KAPA) is drawing trader attention on the first day of its second reverse stock split in three years. The most important number in the capital structure is not the freshly compressed share count — it is the roughly $26.8 million of undrawn capacity sitting inside a standby equity purchase agreement — a facility that lets the company sell newly issued shares to a committed buyer at its own discretion — with Helena Global Investment Opportunities I LTD, a Cayman Islands–domiciled equity-line financier.
That undrawn balance is approximately 6.5 times the post-split float's market value of roughly $4.1 million.
How the equity line works
Helena's facility prices each draw at 95% of the lowest trading price over the three days following each advance notice — meaning the buyer pays a 5% discount to the worst price the stock prints during the look-back window, a mechanic that structurally rewards downward pressure while the pricing period is open. Shareholders voted in June 2025 to remove the NYSE American Rule 713 cap that would otherwise block below-market issuances exceeding 19.99% of shares outstanding.
Critically, the Helena line is registered for resale on a Form S-1 rather than the company's Form S-3 shelf. That distinction matters. The S-3 shelf is currently throttled by the "baby-shelf" rule — a regulation limiting issuers with a public float under $75 million to selling only one-third of that float's value in any rolling twelve-month period. The S-1 registration escapes that constraint entirely, making the equity line the only large-scale issuance channel still fully open.
Post-split structure
The 1-for-7 reverse split, effective September 1, 2026, collapsed shares outstanding from roughly 23.7 million to 3,385,383 and the public float from approximately 17.2 million to an estimated 2,463,051 free-trading shares. Authorized shares were not reduced. They remain at 100 million common and 20 million preferred — leaving roughly 96.6 million shares of unissued headroom, or about 28 times the current outstanding count.
The company carries zero debt, zero preferred stock outstanding, and zero convertible notes. Its 611,577 post-split warrants are all deeply out of the money — strike prices range from $3.22 to $33.60 — with no reset or ratchet provisions that would reprice them downward. Reported intrinsic value at June 30, 2026: zero.
The issuance cadence that preceded the split
Between July 1 and August 12, 2026, the company sold 2,359,326 pre-split shares (337,047 post-split) through its H.C. Wainwright at-the-market program — a facility that sells stock directly into the open market at prevailing prices — for $911,000 in gross proceeds, an implied price of roughly $0.386 per share. That single slug represented 11% of the then-outstanding count in approximately six weeks. The reverse split followed nine days later.
Shares outstanding grew 14.2% over the trailing twelve months. The company has executed eleven distinct capital-raising events in the 24 months since its September 2024 IPO — roughly one every two months.
Cash runway and what it implies
Cash on hand at June 30 was $2.63 million against a quarterly operating burn of roughly $1.02 million, implying about 2.6 quarters of runway. The ATM's usable capacity has collapsed to approximately $50,000 under the baby-shelf constraint. That arithmetic points directly at the Helena equity line as the next financing channel — and any draw against it now lands on a float of just 2.46 million shares, meaning the same dollar raise consumes a far larger percentage of tradeable supply than it would have one week ago.
The equity line runs through December 1, 2027; the binding limit on total issuance is the number of shares registered on the underlying S-1, a figure not disclosed in available filings.